NIH Trial – HERV-E TCR Transduced Autologous T Cells in People with Metastatic Clear Cell Kidney Cancer.
Good News! Since I last shared news of this exciting clear cell kidney cancer trial it has continued to actively recruit. If you are interested there are still spots available. Eligibility criteria include:
- Being at least 18,
- having clear cell RCC,
- measurable disease progression in the last six months;
- and being positive for HLA-A 11:01.
HLA-A 11:01 is only present in a subset of clear cell RCC patients. The NIH, at no charge, can arrange testing for you if you are interested in finding out if you are positive for HLA-A 11:01. Additionally, there are some eligibility requirements related to prior treatments.
The trial involves a 2 to 3 week stay at the NIH and a caregiver is asked to stay with you for these weeks. If this sounds like a fit for you in your treatment plan, contact your oncologist. They can work with you to evaluate the trial and reach out to the NIH.
Anyone who fits the eligibility and is selected for an NIH trial can participate, regardless of where you live or your insurance status. All costs for treatment are covered by the NIH and in many cases, travel costs are also covered.
You can learn more about this trial and get information to share with your doctor here.
If you are interested in seeing information on all trials available for kidney cancer, you can search for them at www.clinicaltrials.gov.
Want to just see trials that are open in kidney cancer at the NIH? Try refining your search to locations in Bethesda, Maryland!
On behalf of KCCure and kidney cancer patients around the world, I want to express my thanks to Dr. Childs and Julie Erb-Alvarez at the NIH, for keeping us up to date on this trial. Knowing the NIH is hard at work looking for cures leaves me very optimistic for the future.
Laura Loughlin is Director of Patient Engagement for KCCure. She is a stage 4 kidney cancer survivor from Boston, MA
